Articles published by Equillium, Inc.
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference
March 22, 2023
From Equillium, Inc.
Via Business Wire
Tickers
EQ
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
December 16, 2022
From Equillium, Inc.
Via Business Wire
Tickers
EQ
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
November 14, 2022
From Equillium, Inc.
Via Business Wire
Tickers
EQ
Equillium to Present at Two Upcoming Investor Conferences
November 08, 2022
From Equillium, Inc.
Via Business Wire
Tickers
EQ
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
November 03, 2022
From Equillium, Inc.
Via Business Wire
Tickers
EQ
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
September 27, 2022
From Equillium, Inc.
Via Business Wire
Tickers
EQ
Equillium to Acquire Metacrine in All-Stock Transaction
September 06, 2022
From Equillium, Inc.
Via Business Wire
Equillium to Present at Two Upcoming Investor Conferences
August 31, 2022
From Equillium, Inc.
Via Business Wire
Tickers
EQ
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
August 15, 2022
From Equillium, Inc.
Via Business Wire
Tickers
EQ
Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit
July 28, 2022
From Equillium, Inc.
Via Business Wire
Tickers
EQ
Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology
April 04, 2022
From Equillium, Inc.
Via Business Wire
Tickers
EQ
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.